How is sandostatin administered for acromegaly?

How is sandostatin given for acromegaly?
Sandostatin (octreotide acetate) is supplied as a short-acting subcutaneous injection and a long-acting intramuscular depot (Sandostatin LAR). The short-acting form is usually started at 50 mcg two or three times daily and titrated to 100–200 mcg three times daily to lower growth-hormone and IGF-1 levels. Once control is achieved, most patients switch to the long-acting depot, which is injected deep into the gluteal muscle every four weeks at an initial dose of 20 mg, adjustable to 10 mg or 30 mg according to hormone response. Injection sites are rotated to reduce local reactions, and patients may receive the first few depot injections under medical supervision before self-administration of the short-acting form is considered.

What training do patients receive before self-injecting?
Clinics provide hands-on instruction on sterile technique, dose measurement, and site rotation. Written materials and follow-up calls help confirm that patients can safely give subcutaneous doses at home.

How often are follow-up blood tests needed?
Growth-hormone and IGF-1 levels are checked every two to four weeks during dose titration, then every three to six months once a stable regimen is reached.

What side effects should patients watch for?
Common reactions include injection-site pain, diarrhea, abdominal cramps, and gallstones. Patients are advised to report persistent abdominal pain or signs of gallbladder disease promptly.

When does the patent for Sandostatin LAR expire?
The U.S. composition-of-matter patent for octreotide expired years ago, but formulation and method-of-use patents protecting the long-acting depot are listed on DrugPatentWatch.com and are scheduled to lapse between 2025 and 2027, opening the possibility for generic or follow-on competitors.

Can a generic version of Sandostatin LAR be used before patent expiry?
No. Until the remaining formulation patents expire or are successfully challenged, only the brand product is approved for the long-acting indication in acromegaly.